Abstract

ObjectivesTo evaluate the success rate of glucocorticoid discontinuation and to study which factors are associated with successful discontinuation.MethodsData from two treat-to-target studies, BeSt (target Disease Activity Score (DAS) ≤2.4) and...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0076 Low Disease Activity or DAS-Remission as Treatment Target in Early Rheumatoid Arthritis Patients
P.B De Sonnaville ... C.F Allaart
Annals of the Rheumatic Diseases | VOL. 75
P.B De Sonnaville, et. al.P.B De Sonnaville ... C.F Allaart
01 Jun 2016
Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis
Cornelia F Allaart ... Tom W J Huizinga
RMD Open | VOL. 4
Cornelia F Allaart, et. al.Cornelia F Allaart ... Tom W J Huizinga
01 May 2018
Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning
Sytske Anne Bergstra ... Gerard Collée
Arthritis Research & Therapy | VOL. 19
Sytske Anne Bergstra, et. al.Sytske Anne Bergstra ... Gerard Collée
30 Sep 2017
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
Cornelia F Allaart ... Lotte Heimans
Arthritis research & therapy | VOL. 18
Cornelia F Allaart, et. al.Cornelia F Allaart ... Lotte Heimans
21 Jan 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers